It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.
The EU doesn’t do fundamental research, which is why it has taken 20 years for researchers involved in high risk research to get together, but it can’t get by without it.
As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?
As governments direct stimulus packages towards science and research, don’t forget the current crop of spin-outs who face extinction in a frozen capital market, writes Nuala Moran.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.